Gilead to buy ‘best biotech comeback’ CymaBay for $4.3 billion

An activist hedge fund two years ago wanted to liquidate 36-year-old CymaBay, which has burned through around $1 billion.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks